Aurinia’s Lupkynis Gaining Traction and Generating High Interest

Aurinia’s Lupkynis Gaining Traction and Generating High Interest

Are Aurinia’s Lupkynis and GSK’s Benlysta for the treatment of LN gaining traction? Are they challenging the standard of care? Is one performing better than the other? Is there a place for both?

Report Date :
09/24/2021
Topic :
Aurinia Pharmaceuticals
Source Silos :
1) AUPH and AZN sales professionals and the founder of a Lupus foundation 2) Secondary sources
Sector :
Health Care
Companies :
AUPH, AZN, GSK
Industry :
Biotechnology

Aurinia’s Lupkynis Gaining Traction and Generating High Interest PDF